ChemicalBook > CAS DataBase List > Urelumab

Urelumab

Product Name
Urelumab
CAS No.
934823-49-1
Chemical Name
Urelumab
Synonyms
Urelumab;BMS-663513;anti-4-1BB antibody;BMS-663513|||BMS-66513;Research Grade Urelumab;Urelumab (anti-TNFRSF9);Research Grade Urelumab(DHG11002)
CBNumber
CB83363719
Formula Weight
0
MOL File
Mol file
More
Less

Urelumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Urelumab Chemical Properties,Usage,Production

Uses

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL)[1].

Biological Activity

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

in vivo

Urelumab (0.3-1 mg/kg, i.p., once every 3 days, 6 times) reduces the tumor volume and tumor weight in humanized 4-1BB mice[2].
Urelumab (3-30 mg/kg, i.p., once every 3 days, 6 times) exhibits high safety in humanized 4-1BB mice[2].

target

4-1BB

References

[1] John Timmerman, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020 May;95(5):510-520. DOI:10.1002/ajh.25757
[2] Cheng LS, et al. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity. J Transl Med. 2022 Sep 8;20(1):415. DOI:10.1186/s12967-022-03619-w

Urelumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Urelumab Suppliers

Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58

934823-49-1, UrelumabRelated Search:


  • Urelumab
  • Research Grade Urelumab(DHG11002)
  • BMS-663513
  • Urelumab (anti-TNFRSF9)
  • BMS-663513|||BMS-66513
  • anti-4-1BB antibody
  • Research Grade Urelumab
  • 934823-49-1